GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59

GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.

Bristol Myers’ KRAS Confirmatory Data Avoid Amgen’s Flaws but Leave FDA Prospect Unclear

Bristol Myers Squibb, KRAS confirmatory data, Amgen, FDA, accelerated approval pathway, oncology therapies, clinical benefits, confirmatory trials